Suresh Mahalingam

TL;DR: This review aims to provide insights into alphavirus-induced bone loss and focuses on aspects of disease exacerbation in patients with underlying arthritis and on possible therapeutic targets.

TL;DR: PPS is a promising new therapy for alphvirus-induced arthritis, acting to preserve the cartilage matrix, which is damaged during alphavirus infection, and demonstrates the potential of glycotherapeutics as a new class of treatment for infectious arthritis.

TL;DR: Evidence from mouse models suggests targeting MCP-1 or complement may emerge as viable new treatment options for viral arthritides, and the challenge for new treatments is to target excessive inflammation without compromising anti-viral immunity.

TL;DR: This work investigates how two alphaviruses, Semliki Forest virus and Ross River virus, reprogram host metabolism and defines the molecular mechanisms responsible and demonstrates that in both cases the presence of a YXXM motif in the viral protein nsP3 is necessary for binding to the PI3K regulatory subunit p85 and for activating AKT.

TL;DR: It is shown that CHIKV replication and the ensuing foot arthropathy were dramatically reduced when mice were housed at 30°C, rather than the conventional 22°C; this may provide an explanation for why alphaviral arthropathies are largely restricted to joints of the limbs and the extremities.